Q4 2025 Zealand Pharma A/S Earnings Call Transcript
Key Points
- Zealand Pharma AS (ZLDPF) reported a strong revenue of DKK9.2 billion for 2025, driven by upfront payments from partnerships.
- The company has a robust cash position of DKK15.1 billion, enabling it to meet obligations and invest in future growth.
- Zealand Pharma AS (ZLDPF) is advancing its metabolic health pipeline with plans to launch five products over the next five years.
- The partnership with Roche for petrelintide is progressing well, with shared profits and strategic rights in the US and Europe.
- The company is leveraging AI and machine learning to enhance its research capabilities and accelerate innovation.
- The obesity treatment landscape remains narrow, with challenges in long-term treatment persistence for GLP-1-based therapies.
- Approximately 50% of patients discontinue GLP-1 therapies due to gastrointestinal adverse events.
- Zealand Pharma AS (ZLDPF) faces competitive dynamics in the obesity market, particularly with the launch of oral GLP-1 therapies.
- The company anticipates high operating expenses in 2026, driven by research and development activities.
- There is uncertainty regarding the pricing strategy for petrelintide upon its launch in the obesity market.
Good day and thank you for standing by. Welcome to the Zealand Pharma results full-year 2025 conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Adam Lange, Vice President, Investor Relations. Please go ahead.
/- -
Thank you, operator, and thank you to everyone for joining us today to discuss Zealand Pharma's results for the full-year 2025. The related company announcement is available on our website at zealandpharma.com. As outlined on slide 2, I would like to remind listeners that during today's call, we will be making forward-looking statements that are subject to risks and uncertainties.
Turning to slide 3 and today's agenda, I have with me on the call the following members of Zealand Pharma's management team: Adam Steenssberg, President and Chief Executive Officer: Henriette Wennicke, Chief Financial Officer; and David
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
